Cited by 365Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchRadiopharmaceutical Chemistry and Applications

The DOI matches its Crossref record; 27 of the 33 references it cites were found in a registry or an index.

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

Open access

Rudnick, Stephen I., Lou, Jianlong, Shaller, Calvin C., Tang, Yong, Klein-Szanto, Andres J.P., Weiner, Louis M., Marks, James D., Adams, Gregory P.·2011·Cancer Research

DOI 10.1158/0008-5472.can-10-2277PMC PMC3077882

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated. In this study, we investigated the impact of antibody binding affinity on tumor targeting and penetration with affinity variants that recognize the same epitope. Specifically, we compared four derivatives of the C6.5 monoclonal antibody (mAb), which recognizes the same HER2 epitope (monovalent KD values ranging from 270 to 0.56 nmol/L). Moderate affinity was associated with the highest tumor accumulation at 24 and 120 hours after intravenous injection, whereas high affinity was found to produce the lowest tumor accumulation. Highest affinity mAbs were confined to the perivascular space of tumors with an average penetration of 20.4 ± 7.5 μm from tumor blood vessels. Conversely, lowest affinity mAbs exhibited a broader distribution pattern with an average penetration of 84.8 ± 12.8 μm. In vitro internalization assays revealed that antibody internalization and catabolism generally increased with affinity, plateauing once the rate of HER2 internalization exceeded the rate of antibody dissociation. Effects of internalization and catabolism on tumor targeting were further examined using antibodies of moderate (C6.5) or high-affinity (trastuzumab), labeled with residualizing (111In-labeled) or nonresidualizing (125I-labeled) radioisotopes. Significant amounts of antibody of both affinities were degraded by tumors in vivo. Furthermore, moderate- to high-affinity mAbs targeting the same HER2 epitope with monovalent affinity above 23 nmol/L had equal tumor accumulation of residualizing radiolabel over 120 hours. Results indicated equal tumor exposure, suggesting that mAb penetration and retention in tumors reflected affinity-based differences in tumor catabolism. Together, these results suggest that high-density, rapidly internalizing antigens subject high-affinity antibodies to greater internalization and degradation, thereby limiting their penetration of tumors. In contrast, lower-affinity antibodies penetrate tumors more effectively when rates of antibody–antigen dissociation are higher than those of antigen internalization. Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors. Cancer Res; 71(6); 2250–9. ©2011 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-2277

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 642
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623
Self-citation
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
Austin, C. D., Mazière, A. M. G. L. D., Pisacane, P. I., van Dijk, S., Eigenbrot, C. W., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 507
Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site
Schier, R., McCall, A. M., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C. B., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0598 · Cited by 382
Self-citation
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection
Schier, R., Bye, J. M., Apell, G., McCall, A. M., Adams, G. P., Malmqvist, M., Weiner, L. M., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0004 · Cited by 291
Self-citation
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1989) · PubMed · Cited by 258
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy‐Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2724 · Cited by 245
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Self-citation

Show all 33 references

Research works printed but not linked: 1

Adams, 1992, Comparison of the pharmacokinetics in mice and the biological-activity of murine L6 and human-mouse chimeric Ch-L6 antibody, Antib Immunoconjug Radiopharm, 5, 81

Sorted by citations

Items 201–300 of 365

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
Kim, H. J., Sung, H. J., Lee, Y. M., Choi, S. I., Kim, Y., Heo, K., & Kim, I.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093286 · Cited by 12
Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology
Rojas, G. (2022) · Antibodies · doi:10.3390/antib11030048 · Cited by 12
Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody
Menezes, B., Khera, E., Calopiz, M. C., Smith, M. D., Ganno, M. L., Cilliers, C., Abu‐Yousif, A. O., Linderman, J. J., & Thurber, G. M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00756-4 · Cited by 12
Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistry
Khan, S., Mejia, F., Shin, J.-H., Hwang, G., Omstead, D. T., Wu, J., Cole, S. L., Littlepage, L. E., & Bilgiçer, B. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121913 · Cited by 12
A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown products
Suzuki, T., Miyazaki, C., Ishii‐Watabe, A., Tada, M., Sakai‐Kato, K., Kawanishi, T., & Kawasaki, N. (2015) · mAbs · doi:10.1080/19420862.2015.1038683 · Cited by 12
Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies
D’Souza, J. W., Reddy, S., Goldsmith, L. E., Shchaveleva, I., Marks, J. D., Litwin, S., & Robinson, M. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112376 · Cited by 12
Self-citation
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
Dalziel, M., Beers, S. A., Cragg, M. S., & Crispin, M. (2018) · Glycobiology · doi:10.1093/glycob/cwy043 · Cited by 12
Plant-derived chimeric antibodies inhibit the invasion of human fibroblasts byToxoplasma gondii
Lim, S. S. Y., Chua, K. H., Nölke, G., Spiegel, H., Goh, W. L., Chow, S. C., Kee, B. P., Fischer, R., Schillberg, S., & Othman, R. Y. (2018) · PeerJ · doi:10.7717/peerj.5780 · Cited by 11
Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody
Park, S.-W., Jun, S.-Y., Kim, J., & Kim, Y. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.021 · Cited by 12
Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment
Li, Z., Wang, M., Yao, X., Li, H., Li, S., Liu, L., Yu, D., Li, X., Fang, J., & Huang, C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.034 · Cited by 12
Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy
Zhu, W., Wang, Y., Lv, L., Wang, H., Shi, W., Liu, Z., Zhou, M., Zhu, J., & Lu, H. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.004 · Cited by 11
It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies
Trommer, J., Ullrich, M., Reissig, F., Brühlmann, S. A., Nitt-Weber, A.-K., Nový, Z., Hajduová, K., Kurfürstová, D., Hendrychová, R., Bouchal, J., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00354-7 · Cited by 11
EGFR targeting of [177Lu] gold nanoparticles to colorectal and breast tumour cells: Affinity, duration of binding and growth inhibition of Cetuximab-resistant cells
Shabbir, R., Mingarelli, M., Cabello, G., van Herk, M., Choudhury, A., & Smith, T. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101573 · Cited by 11
Lectin‐based phototherapy targeting cell surface glycans for pancreatic cancer
Kuroda, Y., Oda, T., Shimomura, O., Hashimoto, S., Akashi, Y., Miyazaki, Y., Furuya, K., Furuta, T., Nakahashi, H., Louphrasitthiphol, P., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34362 · Cited by 11
Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
Максимилианович, Т. В., Васильевна, Б. В., Oroujeni, M., Deyev, S. M., Коновалова, Е. В., Schulga, A. A., Lindbo, S., Hober, S., Bragina, O., Orlova, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315181 · Cited by 11
Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates
Nakashima, K., Watanabe, H., & Ono, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00472 · Cited by 11
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_16 · Cited by 11
Radionuclide imaging of drug delivery for patient selection in targeted therapy
Heskamp, S., van Laarhoven, H. W. M., van der Graaf, W. T. A., Oyen, W. J. G., & Boerman, O. C. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.870552 · Cited by 11
Phenomenon of Endothelial Antibody Capture: Principles and Potential for Locoregional Targeting of Hepatic Tumors
Winkler, N., Strübing, F., Groß, W., Mier, W., & Ryschich, E. (2018) · Hepatology · doi:10.1002/hep.30072 · Cited by 11
Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
Kuo, W.-Y., Hsu, H.-J., Wu, C.-Y., Chen, H.-S., Chou, Y., Tsou, Y.-L., Peng, H., Jian, J.-W., Yu, C.-M., Chiu, Y.-K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1541370 · Cited by 11
Development of a Non-IgG PD-1/PD-L1 Inhibitor by in Silico Mutagenesis and an In-Cell Protein–Protein Interaction Assay
Ning, B., Ren, X., Hagiwara, K., Takeoka, S., Ito, Y., & Miyatake, H. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00817 · Cited by 11
Pseudomonas Exotoxin A-Based Immunotherapy Targeting CCK2R-Expressing Colorectal Malignancies: An In Vitro and In Vivo Evaluation
Chang, J., Liu, X., Ren, H., Lu, S., Li, M., Zhang, S., Zhao, K., Li, H., Zhou, X., Peng, L., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00095 · Cited by 10
Antibody-drug conjugates as drug carrier systems for bioactive agents
Akash, M. S. H., Rehman, K., Parveen, A., & Ibrahim, M. (2015) · International Journal of Polymeric Materials · doi:10.1080/00914037.2015.1038818 · Cited by 10
Utilizing Salmonella to treat solid malignancies
Ebelt, N. D., & Manuel, E. R. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24644 · Cited by 10
IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells
Frontera, E. D., Khansa, R. M., Schalk, D. L., Leakan, L. E., Edbauer, T. G., Ratnam, M., Gorski, D. H., & Speyer, C. L. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4941-5 · Cited by 10
Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study
Pronk, S. D., Schooten, E., Heinen, J., Helfrich, E., Oliveira, S., & Henegouwen, P. M. P. V. B. E. (2021) · Biomolecules · doi:10.3390/biom11070927 · Cited by 10
A homogeneous fluorescence-based method to measure antibody internalization in tumor cells
Gong, H., & Urlacher, T. M. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.09.008 · Cited by 10
Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model
Deneka, A. Y., Haber, L., Kopp, M. C., Gaponova, A. V., Nikonova, A. S., & Golemis, E. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176747 · Cited by 11
HER2-targeted star polymer conjugates for improved tumor distribution and efficacy
Sonzini, S., England, R., Kapustin, A. N., Moss, J. I., Sutton, D., Smith, A., Sharma, S., Siouve, E., Mazza, M., Ravn, P., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113654 · Cited by 9
Utility of Nanomedicine for Cancer Treatment
Akakuru, O. U., Louis, H., Oyebanji, O. O., Ita, B. I., Amos, P. I., & Philip, M. (2018) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000481 · Cited by 9
Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate
Satofuka, H., Wang, Y., Yamazaki, K., Hamamichi, S., Fukuhara, T., Rafique, A., Osako, N., Kanazawa, I., Endo, T., Miyake, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31263-x · Cited by 9
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2
Wichmann, C. W., Burvenich, I. J. G., Guo, N. Y., Rigopoulos, A., McDonald, A. F., Cao, D., O'Keefe, G. J., Gong, S. J., Gan, H. K., Scott, F. E., et al. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108366 · Cited by 9
Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts
Heyerdahl, H., Redalen, K. R., Brevik, E. M., & Dahle, J. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.052 · Cited by 9
Antibody-drug conjugates in cancer therapy�filling in the potholes that lie ahead
Firer, M. (2013) · OA Cancer · doi:10.13172/2053-3918-1-1-753 · Cited by 9
Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy
Urabe, M., Ushiku, T., Seto, Y., & Fukayama, M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000672 · Cited by 9
3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis
Pérez-Treviño, P., la Cerda, H. H. D., Pérez-Treviño, J., Fajardo‐Ramírez, Ó. R., Garcı́a, N., & Altamirano, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.03.004 · Cited by 9
Targeted Maytansinoid Conjugate Improves Therapeutic Index for Metastatic Breast Cancer Cells
Jiang, Z., Yang, Z., Li, F., Li, Z., Fishkin, N. E., & Burgess, K. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00340 · Cited by 9
Exploring the Antitumor Mechanisms of Zingiberis Rhizoma Combined with Coptidis Rhizoma Using a Network Pharmacology Approach
Wang, M., Qi, Y., & Sun, Y. (2020) · BioMed Research International · doi:10.1155/2020/8887982 · Cited by 9
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies
Sepp, A., & Muliaditan, M. (2024) · mAbs · doi:10.1080/19420862.2024.2324485 · Cited by 9
Novel FRET‐based Immunological Synapse Biosensor for the Prediction of Chimeric Antigen Receptor‐T Cell Function
Lee, H. N., Lee, S., Hong, J., Yoo, H., Jeong, J., Kim, Y., Shin, H. M., Jang, M., Lee, C., Kim, H., et al. (2024) · Small Methods · doi:10.1002/smtd.202401016 · Cited by 10
Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application
Parakasikron, N., Chaotham, C., Pithi Chanvorachote, B., Vinayanuwattikun, C., Buranasudja, V., Taweecheep, P., & Khantasup, K. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1943055 · Cited by 8
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
Sandker, G. W., Middelburg, J., Wilbrink, E., Molkenboer‐Kuenen, J. D. M., Aarntzen, E. H. J. G., van Hall, T., & Heskamp, S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007596 · Cited by 8
ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Lopez, M., Crompot, E., Josselin, E., Farina, A. K., Rubis, M., Castellano, R., Fares, J., Wehbe, M., Collette, Y., Charafe‐Jauffret, E., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0176 · Cited by 8
A High-Throughput Magnetic Nanoparticle-Based Semi-Automated Antibody Phage Display Biopanning
Ch’ng, A. C. W., Ahmad, A., Konthur, Z., & Lim, T. S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_18 · Cited by 8
Antibody-drug conjugates: an evolving approach for melanoma treatment
Anderson, T. S., McCormick, A. L., La-Beck, N. M., Saha, D., & Lowe, D. B. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000702 · Cited by 8
Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
Ramos, M. K., Mandikian, D., Sermeño, L. N., King, A. N., Dent, A. T., Ho, J., Ulufatu, S., Lombana, T. N., Spiess, C., Go, M. A. T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1097 · Cited by 8
Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography
Obmolova, G., Teplyakov, A., Malia, T., Wunderler, N., Kwok, D. C., Barone, L. R., Sweet, R. W., Ort, T., Scully, M. S., & Gilliland, G. L. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.005 · Cited by 8
From pathogen to cure: exploring the antitumor potential of Toxoplasma gondii
Alipanahi, P., Khosrojerdi, A., Pagheh, A. S., Hatam‐Nahavandi, K., & Ahmadpour, E. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00673-z · Cited by 7
Persistent Membrane‐Anchored Oligomeric Peptides with Nanopore Formation for Targeted Immune Modulation
Cao, J., Yu, Y., Han, K., Wang, B., Ma, B., Zhang, L., Sun, B., Li, Y., Li, J., Ma, Y., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507700 · Cited by 7
Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma
Rosenblum, L. T., Sever, R. E., Gilbert, R., Guerrero, D. T., Vincze, S. R., Menendez, D. M., Birikorang, P. A., Rodgers, M., Jaswal, A. P., Vanover, A., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05728-0 · Cited by 7
Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity
Tundidor, Y., Ponce, L. F., Chao, L., Solozabal, J., Hust, M., Dübel, S., & Rojas, G. (2020) · Scientific Reports · doi:10.1038/s41598-019-57279-w · Cited by 7
Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model
Wang, J., Giragossian, C., & Hansel, S. B. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.08.019 · Cited by 7
Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review
Frigerio, B., Luison, E., Desideri, A., Iacovelli, F., Camisaschi, C., Seregni, E. C., Canevari, S., & Figini, M. (2021) · Biomedicines · doi:10.3390/biomedicines9121870 · Cited by 7
A Computational Investigation of In Vivo Cytosolic Protein Delivery for Cancer Therapy
Torres, C., Dumas, S., Palacio-Castañeda, V., Descroix, S., Brock, R. E., & Verdurmen, W. P. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040562 · Cited by 7
pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies
Zhang, M., Li, J., Yan, K., Zhou, H., Mei, S., Wang, B., Li, D., Du, X., Liu, M., Zhang, P., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422731122 · Cited by 6
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy
Chen, P., Bordeau, B. M., Zhang, W., & Balthasar, J. P. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01076-z · Cited by 7
Design of 3D spheroid models for drug-response studies of HER2-targeted radiopharmaceuticals
Zelepukin, I. V., Fulterer, L., Elshazli, A. D., Herlina, A. J., & Максимилианович, Т. В. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214621 · Cited by 6
18F-/68Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression
Yang, T., Sun, J., Huang, G., Wang, H., He, Z., Lin, S., Wang, Y., Zhuang, R., Zhang, X., Liu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02016 · Cited by 6
Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6/8 receptors
Ray, C. M. P., Hui-lin, Y., Spangler, J. B., & Gabhann, F. M. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012157 · Cited by 7
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
Li, H., & Li, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-22 · Cited by 6
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Jafari, D., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_15 · Cited by 6
Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation
Chang, K.-H., Kim, M., Hong, G.-W., Seo, M., Shin, Y.-N., & Kim, S. (2012) · Immune Network · doi:10.4110/in.2012.12.4.155 · Cited by 6
Selecting an Optimal Antibody for Antibody- Drug Conjugate Therapy
Ritchie, M. F., Bloom, L., Carven, G. J., & Sapra, P. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-13081-1_3 · Cited by 6
Antibody-drug conjugates
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.345 · Cited by 6
Antibody Affinity
Frenzel, A., Roskos, L. K., Klakamp, S. L., Liang, M., Arends, R., & Green, L. (2014) · doi:10.1002/9783527682423.ch6 · Cited by 6
Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma
Chaturantabut, S., Oliver, S., Frederick, D. T., Kim, J., Robinson, F. P., Sinopoli, A., Song, T., He, Y., Chang, Y. H., Rodriguez, D. J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182417 · Cited by 5
Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity
Onyido, E. K., James, D. H., García-Parra, J., Sinfield, J. K., Moberg, A., Coombes, Z., Worthington, J., Williams, N., Francis, L. W., Conlan, R. S., et al. (2023) · Antibodies · doi:10.3390/antib12040065 · Cited by 5
Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
Stamati, I., Yahioglu, G., Diez-Posada, S., Pomowski, A., Perez-Castro, I., Stewart, A., Bouché, L., Constantinou, A., Stenton, B. J., Saouros, S., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1182 · Cited by 5
Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin
Johdi, N. A., Harman, R., Sanjuan, I., Kousparou, C. A., Courtenay-Luck, N. S., & Deonarain, M. P. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2012.12.002 · Cited by 5
Targeting of Tomato Bushy Stunt Virus with a Genetically Fused C-End Rule Peptide
Marchetti, L., Simón‐Gracia, L., Lico, C., Mancuso, M., Baschieri, S., Santi, L., & Teesalu, T. (2023) · Nanomaterials · doi:10.3390/nano13081428 · Cited by 5
Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy
Lindland, K., Westrøm, S., Dragovic, S. M., Li, R. G., Malenge, M. M., Ho, B., Juzeniene, A., & Bønsdorff, T. B. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1060 · Cited by 5
Single Tumor Imaging with Multiple Antibodies Targeting Different Antigens
Sun, Y., Shukla, G. S., Pero, S. C., Currier, E. A., Sholler, G. L. S., & Krag, D. N. (2012) · BioTechniques · doi:10.2144/000113855 · Cited by 5
High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors
Timmermand, O. V., Nilsson, J., Strand, S., & Elgqvist, J. (2016) · Medical Physics · doi:10.1118/1.4967877 · Cited by 5
Antigenic Sensitivity of Membrane-Proximal Targeting Chimeric Antigen Receptors can be Fine-Tuned through Hinge TruncationPreprint
McComb, S., Nguyen, T., Shepherd, A., Henry, K. A., Bloemberg, D., Marcil, A., MacLean, S., Gilbert, R., Gadoury, C., Pon, R. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.30.360925 · Cited by 5
VISTA‐targeted antibody‐drug conjugates exhibit potent antitumor effects on malignant pleural mesothelioma
Kang, J., Zhang, Z., Zhang, R., Zheng, M., Jiang, C., Yang, H., Tong, A., & Zhang, Y. (2024) · MedComm – Oncology · doi:10.1002/mog2.78 · Cited by 4
Humanised recombinant antibody fragments bind human pancreatic islet cells
Buenafe, A. C., & Streeter, P. R. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.05.006 · Cited by 4
Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads
Lambert, J. M. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00031 · Cited by 4
The Role of MegaMolecule Antibody Structure in Internalization and Signaling
Sykora, D. J., Sridhar, S., Modica, J. A., Yeeravalli, R., Salaria, R. K., Gu, Z., Lesniak, M. S., & Mrksich, M. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00421 · Cited by 3
Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity
Wang, T., Koo, D. J., Tessier, P. M., & Thurber, G. M. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70198 · Cited by 4
Different Influences of Biotinylation and PEGylation on Cationic and Anionic Proteins for Spheroid Penetration and Intracellular Uptake to Cancer Cells
Jung, W. H., You, G., & Mok, H. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2207.07058 · Cited by 3
Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models
Ghazal, D., Zalzala, F., Fisk, J. C., Tati, S., Karacosta, L. G., Morey, S., Olson, J. R., Quataert, S. A., Dy, G. K., & Rittenhouse‐Olson, K. (2022) · Oncotarget · doi:10.18632/oncotarget.28282 · Cited by 3
Bioactivity of recombinant humanized monoclonal antibody against HER2 in-vivo and in-vitro and its mechanism of action in ovarian cancer
Zeng, J., Zhang, H., & Guan, R. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-432 · Cited by 3
Photocrosslinkable, Low-Affinity Affibodies Show Improved Transport and Retention in 3D Tumor Spheroids
Bower, B. M., Curry, S. D., Goodwin, A. P., & Cha, J. N. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c01225 · Cited by 3
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities
Song, S., Liu, Y., Liu, J., & Tai, W. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00588 · Cited by 4
Tumor Effect‐Site Pharmacokinetics: Mechanisms and Impact on Efficacy
Thurber, G. M. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse551 · Cited by 3
Antibody Therapy
Smaglo, B. G., Aldeghaither, D. S., & Weiner, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17021-3 · Cited by 4
Self-citation
Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns
Abdou, H. A., & Awny, S. (2026) · ASIDE Oncology · doi:10.71079/aside.onc.012026464 · Cited by 2
Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety
Collyer, S. E., Stack, G. D., & Walsh, J. J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220401105929 · Cited by 2
Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors
Tassano, M. R., Camacho, X., Freire, T., Perroni, C., da Costa, V., Cabrera, M., García, M. F., Fernández, M., Gambini, J. P., Cabral, P., et al. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0138 · Cited by 2
HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials
Wang, X., Zhao, L., Gao, F., Meng, Y., Yang, J., Zhu, M., Liao, D., Jia, Y., & Kong, F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673358929250213093803 · Cited by 2
Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab ‐117 Against Human Tumors
Tanaka, T., Suzuki, H., Ohishi, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2025) · Cancer Science · doi:10.1111/cas.70103 · Cited by 2
The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA′ enables screening of antibodies for immunotoxin development
Klausz, K., Kellner, C., Derer, S., Valerius, T., Staudinger, M., Burger, R., Gramatzki, M., & Peipp, M. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.02.002 · Cited by 2
Quantitative Determination of Intracellular Bond Cleavage
Walker, J. A., Sorkin, M. R., & Alabi, C. A. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_14 · Cited by 2
Targeted Mass Spectrometry-Based Approach for the Determination of Intrinsic Internalization Kinetics of Cell-Surface Membrane Protein Targets
Ghosh, D., Sugimoto, H., Lee, J. Y., & Qian, M. G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00146 · Cited by 2
Antibody–Drug Conjugates
Liu, X., & Gao, W. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch6 · Cited by 2
Imaging the pharmacokinetics and therapeutic availability of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor modelsPreprint
Sandker, G. W., Middelburg, J., Wilbrink, E., Molkenboer‐Kuenen, J. D. M., Aarntzen, E. H. J. G., van Hall, T., & Heskamp, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.06.543829 · Cited by 2
Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency
Wang, R., Lai, Q., Lu, Y., Zhou, Y. N., Tang, L., Tao, Y., Yao, Y., Yu, L., Liu, Y., Wang, Y., et al. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.07.003 · Cited by 1
Chapter 2: Challenges and Considerations in the Design of Antibody-Drug Conjugates
Jameel, F., Mills, B. J., Moussa, E. M., Sisodiya, V., Cano, T., & Haight, A. R. (2020) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-31415-6_2 · Cited by 1
Variable chain engineering – humanization and optimization approaches
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.111 · Cited by 1
Enhanced Penetration and Retention of an Antibody in the Articular Cartilage Through Aggrecan Binding and Molecular Downsizing
Noguchi, Y., Hoshino, M., Muraoka, M., Gupta, G., Sun, Y., Hironiwa, N., Tu, W., Joyashiki, E., Haraya, K., Kuramochi, T., et al. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03845-z · Cited by 1

Authors: Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P.
Affiliations: Fox Chase Cancer Center (US)
Authors' Affiliations: 1Developmental Therapeutics Program and 2Pathology Department, Fox Chase Cancer Center, Philadelphia, Pennsylvania; 3Department of Anesthesia, University of California, San Francisco, California; and 4Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Colombia
Corresponding author: Adams, Gregory P.
ORCID: Lou, Jianlong
Tang, Yong
Weiner, Louis M.
Marks, James D.
Adams, Gregory P.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-03-14
Volume: 71
Issue: 6
Pages: 2250-2259
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-10-2277
PMC: PMC3077882
OpenAlex: W2103364597
Cited by: 365
References: 33
Citations by year: 2026: 21 · 2025: 32 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 36 · 2020: 30 · 2019: 14 · 2018: 35 · 2017: 19 · 2016: 24 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 17
FWCI: 17.33
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Fox Chase Cancer Center
National Cancer Institute (R01-CA50633, R01CA118159, T32CA009035, R01CA050633)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords: anti-HER2 antibody, antibody affinity, tumor penetration, tumor targeting, antigen uptake, antibody internalization, antibody catabolism, tumor accumulation, trastuzumab, HER2, perivascular spaces, solid tumors
MeSH terms: Animals, Antibodies, Monoclonal, Antibody Affinity, Epitopes, Antigens, Neoplasm, Binding, Competitive, Endocytosis, Female, Humans, Immunoglobulin G, Immunohistochemistry, Indium Radioisotopes, Iodine Radioisotopes, Mutation, Neoplasm Transplantation, Ovarian Neoplasms, Time Factors, Tissue Distribution, Transplantation, Heterologous, Mice, SCID, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks